nepafenac 0.3%
Sponsors
MDbackline, LLC, Intuor Technologies, Inc.
Conditions
CataractCystoid Macular Edema
Unknown Phase
Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%
CompletedNCT02752646
Start: 2016-04-30End: 2017-03-01Updated: 2017-03-07
Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
CompletedNCT03025945
Start: 2013-10-31End: 2017-01-31Updated: 2018-12-14